Investors

Press Releases

Press Releases

May 19, 2023

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

May 18, 2023

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

May 04, 2023

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

Apr 11, 2023

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

Mar 01, 2023

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Feb 23, 2023

Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

Feb 01, 2023

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

Jan 10, 2023

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

Jan 04, 2023

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

Jan 03, 2023

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

Investor Contact

Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com

Media Contact

Todd Cooper
Sr. Vice President, Corporate Affairs
media@kymeratx.com

Sign Up for Email Alerts